Skip to main content
Inmune Bio, Inc. logo

Inmune Bio, Inc. — Investor Relations & Filings

Ticker · INMB ISIN · US45782T1051 US Manufacturing
Open in API
Filings indexed 572 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country US United States of America
Listing US INMB

About Inmune Bio, Inc.

https://www.inmunebio.com/

Inmune Bio, Inc. is a clinical-stage biotechnology company that develops therapies by reprogramming the patient's innate immune system to fight disease. The company's pipeline is focused on treating cancer and neurodegenerative disorders, particularly Alzheimer's disease. Its lead product candidates include XPro1595, a selective inhibitor of soluble Tumor Necrosis Factor (TNF) for treating neuroinflammation, and INKmune®, a tumor-agnostic therapy designed to prime a patient's natural killer (NK) cells to attack cancer. Inmune Bio's clinical development approach prioritizes matching a drug's mechanism of action to patient biology and using patient-centric outcome metrics.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Regulatory Filings Classification · 80% confidence The document is a Form 8-K current report filed under the Securities Exchange Act, containing an “Other Events” disclosure and attaching a press release (Exhibit 99.1) about clinical trial results. It does not present financial statements or earnings figures, nor does it relate to M&A, governance, dividends, management changes, or executive certifications. It is a standard regulatory announcement (press release attachment) that doesn’t fit any more specific category. Therefore, it should be classified as a general regulatory filing (RNS).
2026-06-02 English
DEF 14A - Inmune Bio, Inc. (0001711754) (Filer)
Proxy Solicitation & Information Statement
2026-04-23 English
8-K - INMUNE BIO, INC. (0001711754) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It includes a Regulation FD Disclosure about an Investor Presentation (Exhibit 99.1) that the company intends to use in presentations. The document explicitly states that the presentation is furnished as an exhibit and is not filed for purposes of Section 18 of the Exchange Act. The length of the document is 4319 characters, which is relatively short and mainly serves as an announcement of the presentation rather than the presentation itself. Therefore, this document is an announcement of an investor presentation rather than the presentation or report itself. According to the classification rules, such announcements are best classified as Regulatory Filings (RNS) because it does not contain the full presentation content but only announces its availability as an exhibit to the 8-K filing.
2026-02-27 English
8-K - INMUNE BIO, INC. (0001711754) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content includes an announcement of a press release about a webinar related to a drug development pathway, and it references the press release as an exhibit. The document is short (3719 characters) and primarily serves as a notification rather than a detailed financial or operational report. It does not contain financial statements or detailed management discussion. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-02-23 English
8-K - INMUNE BIO, INC. (0001711754) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes a press release about a webinar event and does not contain financial statements or detailed financial data. The document length is 3618 characters, which is relatively short and mainly serves as an announcement. It references an attached press release as Exhibit 99.1 but does not include the full report or detailed financial information. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-02-19 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or disclosures by a company. The text includes references to press releases about regulatory submissions and FDA meeting minutes, which are furnished as exhibits. The document explicitly states that the information is "furnished" and not "filed," indicating it is an announcement rather than a full report. The length is 4496 characters, which is relatively short and consistent with a current report. There are no detailed financial statements or comprehensive financial data present. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2026-02-13 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.